Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Bristol Myers Squibb has expanded its push into radiopharmaceuticals by licensing a prostate cancer therapy developed by Swiss biotech Philochem in a deal that includes an upfront payment of $350 ...
Update: After a steady run of teasers earlier this year, Ford has officially unveiled the refreshed Taurus for the Middle East and select other markets. While the exterior changes closely mirror those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback